[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605104":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":59,"collaborators":61,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":11,"enrollmentInfo":77,"targetDuration":11,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Clareon™ PanOptix™, toric or no-toc","EXPERIMENTAL",null,[13],"Device: Clareon Panoptix",{"label":15,"type":16,"description":11,"interventionNames":17},"AcrySof™ IQ PanOptix™, toric or no-toric","ACTIVE_COMPARATOR",[18],"Device: Acrysof™ PanOptix™ toric or not, trifocal IOL CE marked, Alcon company.",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DEVICE","Acrysof™ PanOptix™ toric or not, trifocal IOL CE marked, Alcon company.","both of the patient's eyes will be implanted: 1 CPO and the other APO",[15],{"type":21,"name":26,"description":23,"armGroupLabels":27,"otherNames":11},"Clareon Panoptix",[9],[29],{"name":30,"affiliation":31,"role":32},"Dominique MONNET, MD, PhD","Université Paris Cité, Faculté de Santé \u002F UFR de médecine","PRINCIPAL_INVESTIGATOR",[34,39],{"name":30,"role":35,"phone":36,"phoneExt":37,"email":38},"CONTACT","01 58 41 22 01","+33","dominique.monnet@aphp.fr",{"name":40,"role":35,"phone":11,"phoneExt":11,"email":41},"Valérie PLENCE, MSc","valerie.plence-fauroux@aphp.fr",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Assistance Publique - Hôpitaux de Paris, Ophtalomopôle - Hôpital COCHIN","RECRUITING","Paris","Île-de-France Region","75014","France","FR",{"type":52,"coordinates":53},"Point",[54,55],2.3488,48.85341,{"lat":55,"lon":54},[58],{"name":30,"role":35,"phone":36,"phoneExt":37,"email":38},{"type":60,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[62,65],{"name":63,"class":64},"Alcon Research","INDUSTRY",{"name":66,"class":6},"URC-CIC Paris Descartes Necker Cochin","100605104","clareon-panoptix-versus-acrysof-panoptix--prospective-study-comparing-contrast-sensitivity-100605104",false,"NCT07158177","Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity","Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity. Study of Two Different Material of Intra Ocular Multifocal Lenses Aiming to Compare the Effect on Contrast Sensitivity.","CLAYRE","Inclusion Criteria:\n\n* Patients ≥ 18 years of age\n* Patients presenting for cataract surgery in routine clinical practice and eligible for multifocal IOL implantation (toric and non-toric)\n* Patients with grade 2\u002F3 cataract density and comparable visual acuity in both eyes\n* Patient with a pregnancy test (negative pregnancy test), if applicable\n* Patient with signed consent to participate in the study\n* Patient affiliated to a social security scheme or entitled beneficiary\n\nExclusion Criteria:\n\n* Children \\\u003C 18 years of age\n* Pregnancy or breast-feeding in progress or planned during the study.\n* History of anterior (cornea, anterior chamber, sulcus) or posterior (uveal, vitreoretinal) segment pathology, including retinal vascular occlusive disease, retinal detachment or peripheral retinal laser photocoagulation, AMD, glaucoma.\n* Any inflammation of the anterior or posterior segment, whatever the etiology, and\u002For history of any disease with intraocular inflammatory repercussions.\n* Clinically significant corneal pathology (epithelial, stromal and\u002For endothelial) that could have an impact on visual results.\n* Clinically significant moderate or severe dry eye that could affect study measurements.\n* History of intraocular or corneal surgery (refractive or trauma-related).\n* Presence or history of amblyopia or monofixation syndrome.\n* Subjects with conditions that increase the risk of zonular disruption during the phacoemulsification procedure that may affect the centration or postoperative orientation of the IOL.\n* Any other planned eye surgery, including, but not limited to, limbal relaxing incision (LRI)\u002Fastigmatic keratotomy and laser refractive surgery (LASIK).\n* Irregular astigmatism identified by corneal topography\n* Patients under guardianship, curatorship or safeguard of justice, as well as pregnant or breast-feeding women (article L1121-5 of the CSP).1.1\n* Patient under AME","ALL","18 Years",{"count":78,"type":79},40,"ESTIMATED","INTERVENTIONAL",[82],"NA","Retrospective, comparative, interventional, randomized, single-center study, contralateral (the patient's 2 eyes will be implanted: 1 CPO and the other APO) Patients presenting for cataract surgery with a request for presbyopia correction and managed as part of routine clinical practice.\n\nThe main aim of the study is to demonstrate that contrast sensitivity is better with the Clareon PanOptix (CPO) intraocular lens (IOL) compared with the AcrySof PanOptix (APO) IOL 3 months after implantation.",[85],"Cataract and IOL Surgery",[87,88,89],"Multifocal Intra Ocular Lens","Presbyopia Correcting Intra Ocular Lens (PCIOL).","Cataract","2026-03-25",{"date":92,"type":93},"2026-03-30","ACTUAL",{"date":95,"type":93},"2025-10-01",{"date":97,"type":79},"2026-10-15",{"name":5,"class":6},1]